RZLT · Rezolute, Inc.
$4.66
-0.06 (-1.27%)
At close · Aug 20
Market Cap
$445.35M
Shares
96.29M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.66
Open$4.68
Day$4.60–4.71
52W close$1.40–10.94
Avg vol 30d1.2M
Short int16.9M · 17.5% float · 15.0d
Short vol20%
Last earningsMay 20, 2026
DataOct 2020–Aug 2026
Filing10-Q · May 12
Raw chart and full-history price indicators begin at the captured split on Oct 13, 2020; bars on opposite sides are not compared.
Up next
Next earnings call
Aug 26, 2026
Est · unconfirmed
· in 1 wks
FQ1-27 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+6%
above
Price vs 50-day avg
−2%
below
RSI (14)
48
neutral
MACD trend
Negative
52-week position
34%
mid-range
Momentum
relative strength
1-month return
−12%
trailing
6-month return
+45%
trailing
YTD return
+97%
this year
Relative strength
+34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.53% of float · ▲ +3.5% MoM · 15.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
146 holders — near 3-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
EPS growth
+26%
Y/Y
Free cash flow
$-69.3M
Balance sheet
$80.1M
net cash
Quant / Vol
risk profile
Volatility
127%
annualized · 1-yr
Max drawdown
−87%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+6%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
34%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
17.53% of float · ▲ +3.5% MoM · 15.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
146 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $5 · 34%
Range high $11
vs 200-day avg +6%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RZLT
this stock
Rezolute, Inc.
|
$445.35M | +97.5% | — | — | 17.5% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Oct 13, 2020; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RZLT | +1.3% | -12.2% | +45.2% | -1.3% | +97.5% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +3.3% | -15.6% | +34.0% | -3.4% | +85.6% |
Key facts
CIK
1509261
CUSIP
76200L309
13F (30d)
142 filings
138 filers
Visit website
Investor relations